{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:35:48Z","timestamp":1762428948006,"version":"build-2065373602"},"reference-count":43,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T00:00:00Z","timestamp":1762387200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Pemetrexed demonstrates significant efficacy and safety in second-line and single-agent maintenance therapies, and in combination with platinum-based chemotherapy, it serves as the standard first-line treatment for driver-negative advanced non-small cell lung cancer (NSCLC). Although several studies have reported its widespread use and associated adverse effects, reports of pemetrexed-related pigmentation are rare. At present, the mechanism underlying pemetrexed-induced pigmentation remains unknown, and the timing of onset and risk factors are unclear. Here, we report a case of left lung adenocarcinoma (cT2bN2M1 IVB) with bone metastasis. After the third cycle of pemetrexed, pigmentation, numbness, pain, and walking difficulty developed on both feet and the dorsum of the ankles. These symptoms gradually worsened with subsequent chemotherapy cycles. Following neurotrophic treatment with diclofenac sodium gel and mecobalamin, numbness and pain improved, while pigmentation subsided gradually after discontinuation of pemetrexed. In addition, this study retrospectively analyzed nine patients with pemetrexed-induced skin pigmentation and found that the median onset was during the second cycle (range: 1\u201317\u202fcycles). Pigmentation could be widely distributed on the body surface and aggravated with continued pemetrexed therapy. However, pigmentation resolved spontaneously after discontinuation, with individual differences.<\/jats:p>","DOI":"10.3389\/fmed.2025.1697371","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T05:29:28Z","timestamp":1762406968000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics of skin pigmentation caused by pemetrexed: a case report and literature review"],"prefix":"10.3389","volume":"12","author":[{"given":"Leling","family":"Zhou","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,6]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"393","DOI":"10.3969\/j.issn.1006-5253.2024.05.014","article-title":"Interpretation of \"global cancer statistics 2022\"","volume":"31","author":"Zhang","year":"2024","journal-title":"Chin J Hosp Stat"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.lungcan.2012.10.015","article-title":"Second-line pemetrexed versus docetaxel in Chinese patients with locally advanced or metastatic non-small cell lung cancer: a randomized, open-label study","volume":"79","author":"Sun","year":"2013","journal-title":"Lung Cancer"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"3543","DOI":"10.1200\/JCO.2007.15.0375","article-title":"Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non\u2013small-cell lung cancer","volume":"26","author":"Scagliotti","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1186\/1471-2407-12-423","article-title":"A randomized, phase 2 study comparing pemetrexed plus best supportive care versus best supportive care as maintenance therapy after first-line treatment with pemetrexed and cisplatin for advanced, non-squamous, non-small cell lung cancer","volume":"12","author":"Mubarak","year":"2012","journal-title":"BMC Cancer"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1097\/JTO.0b013e318226b5fa","article-title":"A randomized phase 3 trial comparing pemetrexed\/carboplatin and docetaxel\/carboplatin as first-line treatment for advanced, nonsquamous non-small cell lung cancer","volume":"6","author":"Rodrigues-Pereira","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.cllc.2012.10.001","article-title":"A randomized phase II study of pemetrexed in combination with cisplatin or carboplatin as first-line therapy for patients with locally advanced or metastatic non\u2013small-cell lung cancer","volume":"14","author":"Schuette","year":"2013","journal-title":"Clin Lung Cancer"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"2895","DOI":"10.1200\/JCO.2012.47.1102","article-title":"PARAMOUNT: final overall survival results of the phase III study of maintenance pemetrexed versus placebo immediately after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non\u2013small-cell lung cancer","volume":"31","author":"Paz-Ares","year":"2013","journal-title":"J Clin Oncol"},{"key":"ref9","first-page":"183","article-title":"Efficacy and safety of cisplatin plus pemetrexed as a first-line treatment for Japanese patients with advanced non-squamous non-small-cell lung cancer \u2013 a retrospective analysis","volume":"42","author":"Yamaguchi","year":"2015","journal-title":"Gan To Kagaku Ryoho"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1200\/JCO.2004.08.163","article-title":"Randomized phase III trial of pemetrexed versus docetaxel in patients with non\u2013small-cell lung cancer previously treated with chemotherapy","volume":"22","author":"Hanna","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1016\/S1470-2045(16)30498-3","article-title":"Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study","volume":"17","author":"Langer","year":"2016","journal-title":"Lancet Oncol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.1016\/S0140-6736(09)61497-5","article-title":"Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study","volume":"374","author":"Ciuleanu","year":"2009","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/S2213-2600(20)30365-9","article-title":"Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial","volume":"9","author":"Zhou","year":"2021","journal-title":"Lancet Respir Med"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1158\/1535-7163","article-title":"Platinum neurotoxicity pharmacogenetics","volume":"8","author":"McWhinney","year":"2009","journal-title":"Mol Cancer Ther"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"843019","DOI":"10.1155\/2011\/843019","article-title":"Neurotoxicity caused by the treatment with platinum analogues","volume":"2011","author":"Amptoulach","year":"2011","journal-title":"Chemother Res Pract"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"304","DOI":"10.3390\/toxics3030304","article-title":"Current view in platinum drug mechanisms of peripheral neurotoxicity","volume":"3","author":"Chiorazzi","year":"2015","journal-title":"Toxics"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1111\/crj.12226","article-title":"Hyperpigmentation in palms associated with lung adenocarcinoma resolving after chemotherapy","volume":"10","author":"Wu","year":"2016","journal-title":"Clin Respir J"},{"key":"ref19","first-page":"145","article-title":"Efficacy and safety of pemetrexed combined with paclitaxel in the treatment of advanced breast cancer","volume":"21","author":"Qian","year":"2017","journal-title":"J Clin Med Pract"},{"key":"ref20","first-page":"102","article-title":"Efficacy of Aidi injection combined with pemetrexed and cisplatin in the treatment of advanced lung adenocarcinoma","volume":"17","author":"Zhao","year":"2013","journal-title":"J Clin Med Pract"},{"key":"ref21","first-page":"3","article-title":"An overview of folate metabolism: features relevant to the action and toxicities of antifolate anticancer agents","volume":"26","author":"Calvert","year":"1999","journal-title":"Semin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1007\/s12026-014-8528-x","article-title":"Preclinical validation of interleukin 6 as a therapeutic target in multiple myeloma","volume":"59","author":"Rosean","year":"2014","journal-title":"Immunol Res"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2411","DOI":"10.3892\/or.2015.3830","article-title":"Pemetrexed induces apoptosis in malignant mesothelioma and lung cancer cells through activation of reactive oxygen species and inhibition of sirtuin 1","volume":"33","author":"Hwang","year":"2015","journal-title":"Oncol Rep"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0190-9622(98)70361-5","article-title":"Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy","volume":"39","author":"Pujol","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1067\/mjd.2002.120910","article-title":"Nail pigmentation caused by hydroxyurea: report of 9 cases","volume":"47","author":"Aste","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"e2397","DOI":"10.7759\/cureus.2397","article-title":"Hyperpigmentation with capecitabine: part of hand-foot syndrome or a separate entity?","volume":"10","author":"Caprez","year":"2018","journal-title":"Cureus"},{"key":"ref27","first-page":"575","article-title":"Pemetrexed-induced skin pigmentation: a case report","volume":"18","author":"Zhao","year":"2013","journal-title":"Chin J Clin Oncol"},{"key":"ref28","first-page":"2020","article-title":"A case of pemetrexed-induced skin pigmentation in a postoperative non-small cell lung cancer patient","volume":"32","author":"Gong","year":"2017","journal-title":"West China Med J"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3969\/j.issn.1004-583X.2015.04.024","article-title":"A case of pemetrexed-induced skin pigmentation","volume":"30","author":"Yuan","year":"2015","journal-title":"Clin Focus"},{"key":"ref30","first-page":"100","article-title":"A case of pemetrexed-induced acute urticaria and generalized skin pigmentation","volume":"35","author":"Wang","year":"2016","journal-title":"Herald Med"},{"key":"ref31","first-page":"859","article-title":"A case of pemetrexed-induced generalized skin pigmentation and desquamation","volume":"15","author":"Wu","year":"2017","journal-title":"Central South Pharm"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.lungcan.2013.02.019","article-title":"Pemetrexed-induced neutropenic enteritis and severe cutaneous hyperpigmentation in a patient with malignant pleural mesothelioma","volume":"80","author":"Buchinger","year":"2013","journal-title":"Lung Cancer"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.2165\/00128415-201113600-00109","article-title":"Pemetrexed-induced hyperpigmentation of the skin","volume":"31","author":"Schallier","year":"2011","journal-title":"Anticancer Res"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1111\/j.1540-9740.2007.05720.x","article-title":"A complex pattern of melanonychia and onycholysis after treatment with pemetrexed for lung cancer","volume":"6","author":"Dasanu","year":"2007","journal-title":"Skinmed"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1016\/j.mjafi.2018.11.003","article-title":"Pemetrexed and cisplatin-induced linear hyperpigmentation of skin","volume":"76","author":"Vashisht","year":"2020","journal-title":"Med J Armed Forces India"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2165\/00128071-200102040-00006","article-title":"Drug-induced skin pigmentation: epidemiology, diagnosis and treatment","volume":"2","author":"Dereure","year":"2001","journal-title":"Am J Clin Dermatol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"763","DOI":"10.36849\/JDD.2020.4887","article-title":"Post-inflammatory hyperpigmentation: a review of treatment strategies","volume":"19","author":"Shenoy","year":"2020","journal-title":"J Drugs Dermatol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamadermatol.2016.4399","article-title":"Laser treatments for postinflammatory hyperpigmentation: a systematic review","volume":"153","author":"Agbai","year":"2017","journal-title":"JAMA Dermatol"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"60","DOI":"10.13313\/j.issn.1673-4890.2017.1.012","article-title":"Application of Poria cocos in pigmented skin diseases","volume":"19","author":"Shi","year":"2017","journal-title":"Mod Chin Med"},{"key":"ref40","first-page":"392","article-title":"Relationship between pemetrexed-induced skin pigmentation and efficacy of chemotherapy in lung adenocarcinoma","volume":"48","author":"Zhang","year":"2021","journal-title":"Chin J Clin Oncol"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"E1589","DOI":"10.21037\/jtd.2016.12.102","article-title":"Pemetrexed-induced radiation recall dermatitis in a patient with lung adenocarcinoma: case report and literature review","volume":"8","author":"Ge","year":"2016","journal-title":"J Thorac Dis"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.lungcan.2005.06.006","article-title":"Radiation recall dermatitis with pemetrexed","volume":"50","author":"Hureaux","year":"2005","journal-title":"Lung Cancer"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1159\/000350498","article-title":"Management of elderly patients with advanced non-small cell lung cancer: a single-center experience","volume":"59","author":"Fr\u00fch","year":"2013","journal-title":"Chemotherapy"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1697371\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T11:31:04Z","timestamp":1762428664000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1697371\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,6]]},"references-count":43,"alternative-id":["10.3389\/fmed.2025.1697371"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1697371","relation":{},"ISSN":["2296-858X"],"issn-type":[{"type":"electronic","value":"2296-858X"}],"subject":[],"published":{"date-parts":[[2025,11,6]]},"article-number":"1697371"}}